Prepare to Have Your ‘Mind Blown’ by this Serious Psychedelics Play

Now, capital markets have taken to the potential of psychedelics en masse – a market now estimated to be in excess of USD$5 billion and expected total estimated market size could be as high as $100 billion. And on the healthcare side, according to the World Health Organization, depression and anxiety costs the global economy USD$ 1 trillion each year.

This is where companies like Biomind Labs Inc. (BMND) (NEO.BMND, OTC: CRSWF, FSE: 3XI, Forum) are offering investors a still early-stage opportunity into this exciting new therapeutic field. Listed on the NEO Exchange in late July, BMND is a biotech R&D company aimed at transforming biomedical sciences knowledge into novel pharmaceutical drugs and nanotech delivery systems for a variety of psychiatric and neurological conditions. The Company’s main focus is to guarantee patients access to affordable and modern-day treatments and use cases.

The global pharmaceutical industry is expected to witness positive growth as the top pharma companies are at the forefront of the fight against Covid-19. One important aspect to highlight is that this fight plays on the short and mid-term, but the real consequences of the pandemic are expected to stay for a long period of time.

Biomind Labs is playing a key role on the long-term fight through its pharmaceutical approach and diversified portfolio of novel drugs and delivery systems, based on the main psychedelic molecules, DMT, 5-MeO-DMT and mescaline.

Within the portfolio of therapeutic conditions, Biomind Labs targets depression, anxiety, addictive disorders, neurodegenerative disorders, but the main differential with its peers is that the company goes beyond mental health conditions, with special focus on chronic pain and inflammation.


(Click image to enlarge)


In the News

On November 24th, Biomind announced the successful design of an oromucosal solid pharmaceutical form obtained by 3D printing using selective laser sintering – a form that contains, as its active ingredients, certain psychedelic molecules that the company has in its current portfolio of psychedelic candidates. This pharmaceutical form is aimed at alleviating neurological and psychiatric disorders and acting as an anti-inflammatory agent for various inflammatory disorders.

Alejandro Antalich, Chief Executive Officer of Biomind Labs, commented:

“We believe we are the first company in the world to design a pharmaceutical form for psychedelic drug delivery using 3D printing. This paramount step in our rapid evolution towards becoming a pharmaceutical company, was achieved by our team of scientists who have designed a novel pharmaceutical form to be used with our psychedelic candidates. We are very proud of how our research and development division advances in the development of complex products, on-demand products, and customized products, aimed to address a wide range of needs from patients with different mental health conditions.

3D printing allows creating three-dimensional objects layer by layer, thereby achieving products with variable geometries. Inside the universe of pharmaceutical technology, 3D printing allows combining of shapes and stratification of materials; thus, possibly controlling the time and place of drug release. One of the most interesting and potentially exciting results is that doses can be adjusted in real time for the specific needs of each patient.

3D printing of psychedelics could be key to the future of the industry, not just because it allows us to personalize medicine but also for creating sustainable production, while reducing the environmental burden”

Also recently, the company completed development of a thermosensitive nasal gel pharmaceutical dosage form for its N, N-dimethyltryptamine (DMT) and 5-MeO-DMT product candidates. The product candidates are aimed at treating depression, anxiety, addictive disorders, eating disorders, and improving the quality of life of patients suffering from neurodegenerative disorders.

Biomind’s design of the nasal gel consists of an adequate viscosity liquid, which turns into a mucoadhesive gel almost immediately after insertion into the nasal cavity upon contact with the mucosa at body temperature.


In Closing

Biomind Labs is a game changer in the psychedelic industry with a strong commitment to provide patients and the psychiatric community with novel pharmaceuticals that offer a comfortable, safe and efficient use.

Biomind investors should note that this is a novel approach taken by a company leaded by a team of executives and scientists with proven experience working in public companies and with psychedelic molecules, being the first ones in completing a randomized, placebo controlled clinical trial to test a psychedelic substance in treatment resistant depression.


(Click image to enlarge)


For more information on the company, visit www.biomindlabs.com


FULL DISCLOSURE: This is a paid article produced by Stockhouse Publishing.